The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function
Completed
Conditions studied: Breast Cancer, Lymphoma, Chemotherapy Effect
In brief
The overall goal of this project is to determine the effects of anti-cancer chemotherapy on reflex control of blood pressure and vascular function. Recent data have demonstrated that cardiovascular disease-related mortality is the 2nd cause of morbidity and mortality for 7-year cancer survivors treated with chemotherapy. This anti-cancer treatment-mediated cardiotoxicity is a progressive process that begins at the molecular level, progresses to myocardial injury and left ventricular dysfunction, cumulating as heart failure and cardiovascular disease-related mortality. In parallel to these cardiac-specific changes, chemotherapy has also been shown to increase the risk for vascular-related abnormalities. However, the impact of adjuvant treatments on the function and structure of the peripheral vascular system remains poorly understood. With normal aging, two of the most important vascular adaptations to arteries, which strongly contribute to the increased risk of vascular-related and general cardiovascular disease, are an increase in large artery stiffness and dysfunction of the vascular endothelium. Therefore, the overall goal of this project is to determine the effects of anthracycline-based chemotherapy on large and small artery function and structure. The central hypothesis is that this type of cancer therapy results in negative vascular consequences as determined by non-invasive evaluation of spontaneous blood pressure control, carotid artery stiffness, and vascular endothelium-dependent vasodilation. This observational study is designed to increase our understanding of the vascular changes that occur during and following anti-cancer chemotherapy and provide insight into new methods that will decrease cardiovascular disease risk in those treated for cancer.
Key facts
- Study ID
- NCT03062878
- Run by
- Carl Ade, M.S., Ph.D.
- People needed
- 60
- Starts
- 2017-02-01
- Expected to finish
- 2018-08-01
- Last updated by the study team
- 2025-09-02
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Give voluntary consent to participate in the study
- (Group 1) Diagnosed Stage I-III breast cancer or lymphoma cancer with a > 2 year life expectancy
- (Group 1) Current chemotherapy treatment includes anthracyclines
- (Group 2) History of Stage I-III breast cancer or lymphoma cancer with a > 2 year life expectancy
- (Group 2) 1 - 5 years removed from last date of anthracycline-based chemotherapy
You may not qualify if…
- History of clinical cardiovascular disease (Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemia attack (TIA), or peripheral arterial disease presumed to be of atherosclerotic origin)
- Not met the above criteria
- Unable to provide informed consent
Where it is running
- Lafene Health Center — Manhattan, Kansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.